Advisor Resource Council Acquires New Shares in Dynavax Technologies Corporation (NASDAQ:DVAX)

Advisor Resource Council bought a new stake in Dynavax Technologies Corporation (NASDAQ:DVAX - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 93,841 shares of the biopharmaceutical company's stock, valued at approximately $1,157,000. Advisor Resource Council owned about 0.08% of Dynavax Technologies at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in DVAX. Deep Track Capital LP grew its position in Dynavax Technologies by 42.0% in the 4th quarter. Deep Track Capital LP now owns 17,791,486 shares of the biopharmaceutical company's stock worth $227,197,000 after purchasing an additional 5,265,000 shares in the last quarter. Deerfield Management Company L.P. Series C boosted its stake in shares of Dynavax Technologies by 23,990.1% in the 4th quarter. Deerfield Management Company L.P. Series C now owns 5,193,823 shares of the biopharmaceutical company's stock worth $66,325,000 after buying an additional 5,172,263 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Dynavax Technologies by 4.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 4,067,951 shares of the biopharmaceutical company's stock valued at $51,948,000 after acquiring an additional 171,933 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Dynavax Technologies by 1.8% during the fourth quarter. Renaissance Technologies LLC now owns 2,355,278 shares of the biopharmaceutical company's stock valued at $30,077,000 after acquiring an additional 41,000 shares during the last quarter. Finally, D. E. Shaw & Co. Inc. increased its position in shares of Dynavax Technologies by 34.0% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,918,340 shares of the biopharmaceutical company's stock valued at $24,497,000 after acquiring an additional 486,981 shares during the last quarter. 96.96% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. Wall Street Zen cut Dynavax Technologies from a "buy" rating to a "hold" rating in a research report on Tuesday, May 6th. JMP Securities lowered their target price on Dynavax Technologies from $33.00 to $31.00 and set a "market outperform" rating on the stock in a research note on Wednesday, May 7th. Finally, The Goldman Sachs Group cut their price target on shares of Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating on the stock in a report on Thursday, April 17th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $24.00.

Dynavax Technologies Stock Performance

Shares of NASDAQ:DVAX traded down $0.31 during mid-day trading on Friday, reaching $9.99. The company had a trading volume of 5,233,685 shares, compared to its average volume of 2,176,187. Dynavax Technologies Corporation has a one year low of $9.22 and a one year high of $14.63. The company has a current ratio of 11.93, a quick ratio of 10.84 and a debt-to-equity ratio of 0.49. The company's 50-day moving average price is $10.30 and its 200-day moving average price is $12.06. The firm has a market cap of $1.20 billion, a price-to-earnings ratio of -19.21 and a beta of 1.07.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last released its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.03 by ($0.14). Dynavax Technologies had a positive return on equity of 3.59% and a negative net margin of 20.39%. The firm had revenue of $68.16 million during the quarter, compared to analysts' expectations of $70.01 million. As a group, equities research analysts anticipate that Dynavax Technologies Corporation will post 0.32 EPS for the current fiscal year.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.